Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

PURPOSE: Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II trial of bevacizumab, a monoclonal antibody to vas...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Desjardins, Annick, Reardon, David A., Herndon, James E., Marcello, Jennifer, Quinn, Jennifer A., Rich, Jeremy N., Sathornsumetee, Sith, Gururangan, Sridharan, Sampson, John, Bailey, Leighann, Bigner, Darell D., Friedman, Allan H., Friedman, Henry S., Vredenburgh, James J.
Format: Artigo
Jezik:Inglês
Izdano: 2008
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3671765/
https://ncbi.nlm.nih.gov/pubmed/18981004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0260
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki